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Abstract
Background: Alterations in the methylation levels of tumor suppressor genes are considered as one of 
the essential aspects of malignancies. The present study explored the association of O6-methylguanine-
DNA methyltransferase (MGMT) gene promoter methylation, as a tumor suppressor, with some 
organochlorine pesticides (OCPs) in primary brain tumor (PBT) patients.
Methods: The present study was conducted on a total of 73 PBT patients. The patients’ serum was 
analyzed using gas chromatography for seven OCP derivatives. The methylation-specific PCR (MSP) 
method was also used to determine the methylation status of the MGMT promoter. 
Results: The current findings demonstrated that the methylation of MGMT promoter occurred in 
22 out of 34 glioma cases (64%), but in only one out of 35 meningioma cases. No MGMT promoter 
methylation was observed in other PBT, hemangioma, and anaplastic medulloblastoma stages. Besides, 
there were significant associations between MGMT methylation and γ-HCH (odds ratio [OR]: 1.50; 
95% CI: 1.03- 2.40, P = 0.04), 4,4DDE (OR: 1.44; 95% CI: 1.01- 2.05, P = 0.02), 2,4 DDT (OR: 1.23; CI: 
1.04- 1.45, P = 0.03), and 4,4DDT (OR: 1.46; CI: 1.23- 2.15, P = 0.02) in glioma patients.
Conclusion: The results of the study suggested that the hypermethylation of the MGMT promoter in 
glioma patients is associated with increased OCPs in their serum, especially γ- HCH, 4,4DDE, 2,4DDT, 
and 4,4DDT. Moreover, it may lead to the hypermethylation of the MGMT promoter gene. Hence, it can 
be concluded that exposure to OCPs may potentially induce glioma. 
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Introduction
Despite an enormous amount of research and rapid 
developments during the past decade, there is no definitive 
cure for cancer even though it is believed to be preventable. 
Only 5%–10% of all cancer cases can be attributed to 
genetic defects, whereas the remaining 90%–95% are 
associated with environmental pollutants and lifestyle (1). 
Because of their slow degradation and high persistence in 
the environment, organochlorine pesticides (OCPs) are 
considered as one of the most critical types of environmental 
pollutants with a high human exposure rate (2). Moreover, 
given the bioaccumulation of OCPs in fatty tissues, these 
pesticides have been observed in various human tissues 
in enormous amounts (2). Previous studies have shown 
that long-term exposure to these pesticides increases the 
risk of developing multiple types of cancer (3-5). One of 
the critical mechanisms considered to be associated with 
the role of pesticides in the development of cancers is 
epigenetic modifications (6). As a well-known epigenetic 
modification, DNA methylation occurs in CpG islands 
without making any DNA sequence alterations (7). In an 
in vitro study, Zhang et al showed that pesticide exposure 
could alter DNA methylation levels (8). This paper was 
focused on O6-methylguanine-DNA methyltransferase 
(MGMT) methylation in primary brain tumor (PBT) 
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and meningioma. Glioma accounts for more than 70% of 
all brain tumors including pilocytic astrocytoma (grade I), 
astrocytoma (grade II), anaplastic astrocytoma (grade III), 
and Glioblastoma multiforme (grade IV). Meningioma 
accounts for the remaining 30% of brain tumors, such 
as meningioma (grade I), schwannoma (grade II), and 
lymphoma (grade III) (9). The MGMT gene encodes 
an enzyme that repairs the damage caused by DNA 
alkylating agents (10). Previous studies have shown that 
the lack of MGMT gene function in cancer cells is caused 
by the gene promoter hypermethylation, which leads to 
MGMT gene silencing (11,12). Another study provided 
direct experimental evidence showing that pesticides 
are associated with changes in promoter methylation in 
numerous genes such as MGMT that is reported to be 
involved in the increased risk of cancer development in 
humans (8). Kreth et al, in their review study, pointed 
out that hypermethylation mostly occurs at the CpG 
islands of the MGMT promoter in glioma. Moreover, the 
methylation patterns differ among different glioma grades 
(13). The present study sought to investigate whether 
OCPs derivatives are associated with the MGMT promoter 
methylation regarded as an important tumor suppressor 
in PBT. For this purpose, glioma patients’ serum was 
analyzed using gas chromatography for seven derivatives 
of OCPs, i.e. α -HCH, β -HCH γ -HCH, 4,4DDE, 2,4DDT, 
and 4,4DDT. Furthermore, methylation status of MGMT 




The present study was conducted on 73 patients admitted 
to Shahid Bahonar hospital of Kerman University of 
Medical Sciences, Kerman, Iran from February 2017 to July 
2019. The patients were diagnosed with a brain tumor and 
underwent surgery. They were selected based on clinical 
examination and pathological findings by an expert 
neurosurgeon. The patients’ PBT stage was determined 
based on the tumor node metastasis staging system. All 
patients who had any history of surgery, radiotherapy, and 
chemotherapy, or metastasized cancer from other tissues 
to the brain were excluded from the study. Following the 
surgery, tissue specimens were obtained from the patients 
and immediately frozen at –80°C until further analysis. 
The PBT patients’ mean age and BMI were 49.5 years and 
26.54, respectively. Besides, over half of the patients (55%) 
were engaged in farming activities (Table 1). Of 73 PBT 
patients, 45% and 55% were men and women, respectively 
(Table 1), and most of them had a meningioma (48%) 
(Table 2). 
Sample and data collection
Blood samples were collected from the studied patients 
before surgery and were then centrifuged to separate 
serum elements. Then, the samples were divided into 
single-use aliquots and kept frozen at -80 °C for further 
assessment. The PBT patients’ serum was used for the 
measurement of OCPs via gas chromatography. The 
tumor tissue samples were acquired from the PBT patients 
following surgery and then frozen at -80°C until further 
analysis. The tissue specimens were used to assess MGMT 
methylation through the MSP method. 
Methylation-specific PCR
Using Favorgen Kit (Cat No. FATGK001), the patients’ 
DNAs were extracted and kept at -80 until further 
assessment.
The basis of the MSP method is DNA reaction with 
sodium bisulfite, which leads to the conversion of cytosine 
to uracil and subsequently to thymidine in PCR steps. Still, 
methylated cytosine remains unchanged (14). According 
to a method proposed by Tiwari et al (15), extracted DNA 




Gender, No. (%) 0.15b
Male 18 (52) 13 (37)
Female 16 (47) 22 (63)
Age (year)
Min-Max 47.34± 2.35 49.00± 2.63 0.63
a
BMI (kg/m2) 25.28± 0.56 26.14 ± 0.62 0.30a
Education level, No. (%) 0.95b
High school or less 20 (59) 22 (63)
Greater than high school 14 (41) 13 (37)
Residence, No. (%) 0.01b
North of Kerman 20 (59) 10 (28)
South of Kerman 14 (41) 25 (72)
Farming activities, No. (%) 0.49b
No 14 (41) 17 (48)
Yes 20 (59) 18 (52)
Smoking, No. (%) 0.23b
No 13 (38) 20 (57)
Yes 21 (62) 15 (43)
Family history of cancer, 
No. (%) 0.64
b
No 19 (56) 17 (48)
Yes 15 (44) 18 (52)
TG (mg/dL) 108.95 ± 11.46 140.11 ± 11.69 0.06 c
Cholesterol (mg/dL) 154.68 ± 9.18 161.74 ± 9.13 0.58 c
HDL (mg/dL) 38.70 ± 1.70 39.11 ± 2.33 0.88 c
LDL (mg/dL) 95.18 ± 7.37 94.60 ± 7.26 0.96 c
Abbreviations: BMI, Body mass index; TG, triglycerides; HDL, high-density 
lipoprotein; LDL, low-density lipoprotein. 
P value demonstrates the differences between the glioma and the 
meningioma patients. A significant difference (P˂0.05). Continuous and 
categorical values are expressed as mean ± SD. 
a Independent sample t test; b Chi-square/Fisher exact test; c Mann-Whitney 
U test.
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was treated with sodium bisulfite. The modified DNA 
sequence was amplified by PCR with specific primers of 
methylated and unmethylated DNA (Table 3). Methylated 
primers detect unchanged cytosines, and unmethylated 
primers identify thymines derived from modified cytosines 
in the MGMT promoter region. After PCR, the products 
were loaded on 2% agarose gel, and electrophoresis was 
performed. Then, the results were interpreted based on 
the presence or absence of the relevant band in the agarose 
gel (Figure 1B).
Measuring the organochlorine pesticides in the patients’ 
serum
The standards of seven OCPs derivatives were purchased 
from Pestana (Germany), and 4,4-dichlorobenzophenone 
(the internal standard) was acquired from Sigma-Aldrich 
(USA).
OCPs residues were extracted using hexane and sulfuric 
acid according to the method offered by Zumbado et al 
(16). In summary, the internal standard was added to 0.5 
mL of serum. The specimens were extracted two times, 
with 2 mL of hexane. Then, 200 µL of concentrated 
sulfuric acid was added to the combined extract, leading 
to the separation of its organic part, which was dehydrated 
using 200 mg of anhydrous sodium sulfate. Upon 
centrifuging, the organic layer was entirely concentrated 
at room temperature. After evaporation of the solvent, 
the addition of 100 µL of ethyl acetate made the samples 
ready for injection into the gas chromatography (GC-FID, 
Agilent 7890A, USA). 
Statistical analysis
All continuous variables were presented as mean ± 
standard deviation and categorical variables as numbers 
(percentages). The Kolmogorov-Smirnov test was used 
to check the normality of the variables. The quantitative 
and qualitative variables between glioma and meningioma 
patients were compared using the independent 
samples t-test, Mann-Whitney U test, chi-square, and 
Fisher’s exact test. The associations between OCPs and 
methylation status of MGMT in the glioma patients were 
estimated using the continuous logistic regression model 
adjusted for age, BMI, total lipids, farming activities, and 
place of residence. To examine whether the methylation 
status of MGMT could modify the effects of OCPs 
exposure in glioma, the patients were divided into low 
or high exposure categories based on the median serum 
concentrations of OCPs. Afterward, the logistic regression 
was applied to investigate possible interactions between 
MGMT methylation and OCPs exposure. All analyses 
were performed by SPSS 21.0 for Windows (IBM/SPSS 
Inc., New York, USA). P values less than 0.05 were 
considered significant.
Results
The current findings showed the methylation of the 
MGMT gene in 22 out of 34 glioma cases (64%), along 
with the methylation of the MGMT gene in only one 
out of 35 meningioma cases. However, no methylation 
was observed in the MGMT promoter in other PBT, 
hemangioma, and anaplastic medulloblastoma stages 
(Figure 1A). 
The results of this study also revealed that 76% of the 
PBT patients, hypermethylated in MGMT promoter, 
had body mass index (BMI) above 25, and that 52% of 
patients who were unmethylated in MGMT promoter 
had BMI<25 (Figure 2). Moreover, the results showed 
that 76% of the patients who were hypermethylated in 
MGMT promoter were farmers and that 56% of patients 
who were unmethylated in MGMT promoter had no 









Pilocytic Astrocytoma (grade I) 5 (6.8) 12.41 ± 12.04
Astrocytoma (grade II) 6 (8.2) 3.37 ± 3.71
Anaplastic astrocytoma (grade III) 8 (11) 5.56 ± 8.36
Glioblastoma multiforme (grade IV) 15 (20.5) 25.88 ± 31.85
Meningioma
35 (48)
Meningioma 18 (24.6) 19.78 ± 18.62
Schwannoma 10 (13.6) 30.60 ± 38.75
Lymphoma 7 (9.6) 14
Other
4 (5.5)
Haemangioma 3 (4.1) 2.87 ± 3.0
Anaplastic medulloblastoma 1 (1.4) 1.75 ± 0.35
Table 3. Primer sequences, annealing temperature, and amplicon sizes of MGMT in MSP
Gene name Primer sequences (5-3) forward Primer sequences (5-3) reverse Annealing temperature Product size (bp)
Methylated TTTCGACGTTCGTAGGTTTTCGC GCACTCTTCCGAAAACGAAACG 68 81
Unmethylated TTTGTGTTTTGATGTTTGTAGGTTTTTGT AACTCCACACTCTTCCAAAAACAAAACA 64 93
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agricultural activity (Figure 2). No significant relationship 
was found between MGMT methylation status and tumor 
size in the PBT patients. The mean pesticides levels in the 
methylated and unmethylated status of the MGMT gene 
in the glioma patients are shown in Table 4. The mean 
levels of γ- HCH (P = 0.019), 4,4DDE (P = 0.037), 2,4DDT 
(P = 0.006) and 4,4DDT (P = 0.043) were statistically 
different between the unmethylated and methylated of 
MGMT gene. After adjusting for confounders, age, BMI, 
total lipids, farming activities, and place of residence, 
odds ratio showed that there were significant associations 
between MGMT methylation and γ-HCH (odds ratio 
[OR]: 1.50; 95% CI: 1.03- 2.40, P = 0.04), 4,4DDE (OR: 
1.44; 95% CI: 1.01- 2.05, P = 0.02), 2,4 DDT (OR: 1.23; CI: 
1.04- 1.45, P = 0.03), and 4,4DDT (OR: 1.46; CI: 1.23- 2.15, 
P = 0.02) in the glioma patients (Table 5). Furthermore, in 
the interaction analysis, after adjusting for confounders 
(age, BMI, total lipids, farming activities, and place of 
residence), significant interactions were observed between 
MGMT methylation and OCPs (Figure 3). The adjusted 
odds ratio (AOR) for glioma patients with methylated 
MGMT and exposure to high-level OCPs suggested that 
glioma risk was elevated 4.80 folds for ƩHCHs (the molar 
sums of α –HCH, β-HCH, and γ –HCH), 5.66 folds for 
Ʃ DDEs (the molar sums of 2,4 DDE and 4,4 DDE), and 
6.25 folds for Ʃ DDTs (the molar sums of 2,4 DDT and 4,4 
DDT) compared to the reference.
Discussion
Alterations in the methylation levels of tumor suppressor 
genes are considered as one of the crucial aspects of 
malignancies (3). This study investigated the methylation 
status of MGMT, a tumor suppressor, in 73 PBT patients. 
MGMT gene expression can be silenced by promoter 
methylation. Hypermethylation in specific regions of the 
MGMT promoter was reported in some malignancies 
including gliomas, colorectal cancer, breast cancer, 
and melanoma (14). Previous studies have shown that 
hypermethylation mostly occurs in MGMT promoter 
CpG islands and that the methylation patterns differ 
among different glioma grades (13). A study conducted 
by Zhang et al provided direct experimental evidence 
that pesticides are associated with changes in promoter 
CpG methylation in numerous genes such as MGMT that 
increased cancer risk in humans (8). The findings of the 
present study demonstrated methylation of the MGMT 
gene promoter in 64% of gliomas. Different studies have 
reported the mean methylation of the MGMT gene in 
glioma as 40-74% (17). In the present study, a significantly 
higher percentage of MGMT methylation was found in 
high-grade gliomas (glioblastoma multiform, 13 of 15 
cases), which may account for the deterioration of patients 
Figure 1. (A) The bar graph shows the percentage of different 
statuses of MGMT promoter methylation in PBT patients. Chi-
square test was utilized. (B) the electrophoresis picture of the 
methylation statuses of MGMT promoter regions by MSP. L: 
DNA ladder; M: methylated band; U: Un-methylated band. The 
methylated band is 81 bp and the unmethylated band is 93 bp.
Figure 2. (A) The percentage of different statuses of MGMT 
promoter methylation in PBT patients based on BMI. (B) The 
percentage of different statuses of MGMT promoter methylation 
in PBT patients based on farming activities. (C) The percentage of 
different statuses of MGMT promoter methylation in PBT patients 
based on tumor size.
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in high grades. Unlike gliomas, MGMT is unmethylated 
in the majority of meningiomas. No methylation of the 
MGMT gene was identified in meningioma grades I and II. 
Only one tumor had methylation in the MGMT promoter 
in meningioma grade III, and no methylation was 
observed in other stages of PBT including hemangioma 
and anaplastic medulloblastoma. Therefore, due to the 
absence of methylation in the MGMT gene promoter 
region within meningioma, hemangioma, and anaplastic 
medulloblastoma patients, it can be suggested that this 
methylation is specifically associated with glioma.
The results of this study also showed that the patients 
with BMI above 25 were more likely to have methylation in 
the promoter of the MGMT gene. It is evident that as BMI 
increases, so does body fat mass. Given the fat-solubility 
of OCPs, the results of this study showed that increased 
levels of BMI lead to rises in the amount of the pesticides 
in the fatty tissues, hence confirming its harmful effects 
on health. This finding is in line with previous studies 
that demonstrated an association between overweight 
and methylation of DNA (14,18). The present study also 
revealed that the patients who were farmers or engaged in 
agricultural activities were more likely to have methylation 
in the MGMT gene promoter. Accordingly, Benedetti et 
al demonstrated that long-term exposure to pesticides 
induced hypermethylation of DNA in soybean farmers 
which may be critical for the development of adverse 
health effects such as cancer (19). Furthermore, due to the 
high methylation frequencies of the MGMT promoter in 
glioma patients, this study also investigated the possible 
associations between methylation of the MGMT promoter 
Table 4. The mean levels of OCPs in methylated and unmethylated status 
in glioma patients
Glioma (n= 34)
OCPs Unmethylated (n=12) Methylated (n=22) P value
α–HCH 1.67 ± 0.96 1.54 ± 0.85 0.57
β–HCH 0.73 ± 0.50 0.62 ± 0.40 0.70
γ–HCH 0.70 ± 0.43 1.39 ± 1.01 0.019
2,4 DDE 5.47 ± 2.83 5.40 ± 2.32 0.92
4,4 DDE 1.22 ± 0.91 1.92 ± 1.23 0.037
2,4 DDT 4.88 ± 2.23 7.07 ± 4.33 0.006
4,4 DDT 3.07 ± 1.37 5.70 ± 1.09 0.043
P value demonstrates the difference between unmethylated and methylated 
states.
Significance difference (P < 0.05).
Table 5. Association between OCPs and methylation status of MGMT in 
glioma patients
OCPs Unadjusted OR(95% CI) P value
Adjusted ORa
(95% CI) P value
α–HCH 0.77(0.39- 1.49) 0.57
0.85
(0.49- 1.47) 0.55
β–HCH 0.67(0.22- 2.05) 0.69
0.85
(0.38- 1.88) 0.37
γ–HCH 1.63(1.02- 2.62) 0.03
1.50
(1.03- 2.40) 0.04
2,4 DDE 0.89(0.70- 1.13) 0.91
0.99
(0.82- 1.19) 0.44
4,4 DDE 1.58(1.03- 2.40) 0.04
1.44
(1.01- 2.05) 0.02
2,4 DDT 1.38(1.11- 1.70) 0.01
1.23
(1.04- 1.45) 0.03
4,4 DDT 1.87(1.12- 3.132) 0.02
1.46
(1.23- 2.15) 0.016
Abbreviations: OR, odds ratio; CI, confidence intervals for the OR. 
a Multiple logistic regression. Models were adjusted for age, BMI, total 
lipids, farming activities, and place of residence.
Significant difference (P˂0.05).
Figure 3. interactions of OCPs exposure and MGMT methylation 
in glioma risk. OCP exposure is categorized into high level and low 
level according to concentration medians. AOR (adjusted odds 
ratio) was adjusted for age, BMI, total lipids, farming activities, 
and place of residence and express the relative risk of glioma. 
Low risk was defined as AOR=1.
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and OCPs in the serum of those with gliomas. Measurement 
of OCPs by GC demonstrated that the levels of γ- HCH, 
4,4DDE, 2,4 DDT, and 4,4 DDT were significantly higher 
in the patients with methylated MGMT gene than in the 
unmethylated individuals. Logistic regression analysis 
also demonstrated significant associations between 
MGMT methylation and γ- HCH, 4,4DDE, 2,4DDT, and 
4,4DDT in the gliomas. Moreover, to examine whether 
the methylation status of MGMT could modify the effects 
of OCPs exposure in gliomas, the patients were divided 
into low or high exposure categories based on the median 
OCPs concentrations of the patients’ serum, and then 
logistic regression was applied to investigate the possible 
interactions between MGMT methylation and OCPs 
exposure. To the best of our knowledge, this is the first 
study showing that the exposure to high levels of OCPs 
exposure statistically interacted with MGMT methylation 
and was associated with an elevated risk of glioma. In 
other words, the exposure to high levels of OCPs was 
associated with elevated glioma risk, particularly among 
the individuals with methylated MGMT promoter region. 
Therefore, the present study supports the hypothesis that 
OCPs exposure might lead to epigenetic modifications 
such as promoter methylation of the MGMT promoter 
gene. By the same token, Sabarwal and colleagues’ study 
showed OCPs lead to DNA methylation in humans (20). 
In agreement with the findings of the present study, Tian 
et al indicated a significant association between OCPs 
exposure and methylation of tumor suppressor genes in 
hepatocellular carcinoma (21). In another study, it was 
shown that upon OCPs exposure, DNA methyltransferases 
were upregulated in MCF-7 cells (2). To the best of our 
knowledge, this is the first study to examine the association 
between methylation patterns of the MGMT promoter 
and OCPs in patients with brain cancer.
Conclusion
This study demonstrated that hypermethylation of the 
MGMT promoter is statistically related to the risk of 
gliomas. Given that the MGMT promoter is unmethylated 
in a majority of meningiomas, this methylation appeared 
to be specific to gliomas. These findings also suggest that 
hypermethylation of the MGMT promoter in glioma 
patients is associated with increased concentrations of 
OCPs derivatives in patients’ serum, especially γ- HCH, 
4,4DDE, 2,4DDT, and 4,4DDT. Therefore, OCPs exposure 
may lead to the hypermethylation of the MGMT promoter 
gene in the brain, thereby inducing gliomas. However, 
further studies are needed to determine the exact 
contribution of OCPs to other related factors and tumor 
suppressor genes in gliomas.
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